



# Enroquin<sup>®</sup> (enrofloxacin)

Antibacterial Injectable Solution 2.27%

- Enroquin<sup>®</sup> (enrofloxacin) Injectable Solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin
- Therapeutically equivalent to the pioneer drug
- 20 mL of solution in a glass vial



To order, please contact your Dechra Representative or call (866) 683-0660.

For more information, visit [www.dechra-us.com](http://www.dechra-us.com).

**Important Safety Information:** As with all drugs, side effects may occur. For use in dogs only. Federal law prohibits the extra label use of this drug in food producing animals. Quinolone-class drugs should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. Quinolone-class drugs have been associated with cartilage erosions in weight-bearing joints and other forms of arthropathy in immature animals of various species. The use of enrofloxacin is contraindicated in small and medium breed dogs during the rapid growth phase (between 2 and 8 months of age). The safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. The use of this product in cats may result in retinal toxicity. Refer to the prescribing information for complete details or visit [www.dechra-us.com](http://www.dechra-us.com).

24-hour Veterinary Technical Support: (866) 933-2472 · [support@dechra.com](mailto:support@dechra.com)

ANADA 200-708, Approved by FDA  
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dechra is a registered trademark of Dechra Pharmaceuticals PLC. C220049

